+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anthrax Treatment Market 2019-2023 - Product Image

Global Anthrax Treatment Market 2019-2023

  • ID: 4704123
  • Report
  • November 2018
  • Region: Global
  • 103 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions
  • MORE
The increase in funding for research on anthrax vaccine across the globe is likely to boost the market growth. The new funding will allow additional vaccine characterization and inspection of mucosal immune response. The analysts have predicted that the anthrax treatment market will register a CAGR of more than 8% by 2023.

Market Overview

Development of novel therapies for treatment of anthrax
There has been an increase in the development of novel therapies for anthrax due to the increasing threat of exposure to Bacillus anthracis among civilian populations and military forces.

Challenges associated with early diagnosis

There are challenges associated with early diagnosis of anthrax. Several anthrax cases have gone undetected. Such cases pose a threat to the anthrax treatment market.

For the detailed list of factors that will drive and challenge the growth of the anthrax treatment market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Bayer, and Emergent BioSolutions the competitive environment is quite intense. Factors such as the increase in development of new therapies and increase in research funding, will provide considerable growth opportunities to anthrax treatment manufactures. Bayer, Elusys Therapeutics, and Emergent BioSolutions are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities. Several companies are developing vaccines and therapeutics for bioterrorism-associated anthrax including Elusys Therapeutics.’
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS
  • Pipeline analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Vaccine - Market size and forecast 2018-2023
  • Drug therapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Increase in research funding
  • Increase in development of new therapies
  • Development of vaccines against bioterrorism-associated anthrax
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions
PART 16: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs in clinical trials
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Market condition - Five forces 2018
Exhibit 16: Product - Market share 2018-2023 (%)
Exhibit 17: Comparison by product
Exhibit 18: Vaccine - Market size and forecast 2018-2023 ($ millions)
Exhibit 19: Vaccine - Year-over-year growth 2019-2023 (%)
Exhibit 20: Drug therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Drug therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Market opportunity by product
Exhibit 23: Customer landscape
Exhibit 24: Market share by geography 2018-2023 (%)
Exhibit 25: Geographic comparison
Exhibit 26: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 28: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 30: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 32: Key leading countries
Exhibit 33: Market opportunity
Exhibit 34: Impact of drivers and challenges
Exhibit 35: Vendor landscape
Exhibit 36: Landscape disruption
Exhibit 37: Vendors covered
Exhibit 38: Vendor classification
Exhibit 39: Market positioning of vendors
Exhibit 40: Bayer - Vendor overview
Exhibit 41: Bayer - Business segments
Exhibit 42: Bayer - Organizational developments
Exhibit 43: Bayer - Geographic focus
Exhibit 44: Bayer - Segment focus
Exhibit 45: Bayer - Key offerings
Exhibit 46: Elusys Therapeutics - Vendor overview
Exhibit 47: Elusys Therapeutics - Organizational developments
Exhibit 48: Elusys Therapeutics - Key offerings
Exhibit 49: Emergent BioSolutions - Vendor overview
Exhibit 50: Emergent BioSolutions - Business segments
Exhibit 51: Emergent BioSolutions - Organizational developments
Exhibit 52: Emergent BioSolutions - Key offerings
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions
  • MORE
Global Anthrax Treatment Market 2018-2022

The author of the report recognizes the following companies as the key players in the global anthrax treatment market: Bayer, Elusys Therapeutics, and Emergent BioSolutions.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increase in funding for research on anthrax vaccine across the globe.”

According to the report, one of the major drivers for this market is the development of novel therapies for treatment of anthrax.

Further, the report states that one of the major factors hindering the growth of this market is the Challenges associated with early diagnosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions
Note: Product cover images may vary from those shown
Adroll
adroll